title: The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.
abstract: To determine the effect of systemic thrombolysis with low-dose recombinant tissue plasminogen activator (rtPA) and the body-weight adjusted platelet GPIIb/IIIa receptor antagonist tirofiban, the authors performed lesion volumetry on magnetic resonance perfusion and diffusion images recorded before thrombolysis and on T2-weighted magnetic resonance images on day 8. Treatment with rtPA and tirofiban (n = 13) resulted in a 50% lesion reduction (p < 0.03), while lesion reduction was less in rtPA treatment (n = 16) and absent in nontreated patients (n = 18).
authors.affiliation: Department of Neurology, Heinrich-Heine University of Düsseldorf, Germany. seitz@neurologie.uni-duesseldorf.de
authors.forename: R J
authors.initials: RJ
authors.lastname: Seitz
authors.forename: S
authors.initials: S
authors.lastname: Meisel
authors.forename: M
authors.initials: M
authors.lastname: Moll
authors.forename: H-J
authors.initials: HJ
authors.lastname: Wittsack
authors.forename: U
authors.initials: U
authors.lastname: Junghans
authors.forename: M
authors.initials: M
authors.lastname: Siebler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007091:Image Processing, Computer-Assisted; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008274:Magnesium / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D000077466:Tirofiban; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D011994:Recombinant Proteins; D014443:Tyrosine; D006493:Heparin; D010959:Tissue Plasminogen Activator; D000077466:Tirofiban; D008274:Magnesium